Dec 20, 2018

Starpharma’s $142M+ US license deal for VivaGel® BV featured in Proactive Investors

Starpharma’s $142M+ US license deal for VivaGel® BV featured in Proactive Investors

Online investor portal Proactive Investors highlighted Starpharma’s VivaGel® BV US license deal with ITF Pharma, worth $142 million plus escalating double digit royalties. The piece noted ITF Pharma’s strong pedigree in women’s health and their high-calibre team.

To read the article, click here.

 This contains certain forward-looking statements.